Post-earnings recap
Reported
Tue, Mar 28, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kodiak Sciences reported a larger-than-expected loss per share, which was a positive surprise compared to expectations, but they did not provide revenue figures. The stock reacted slightly down by 0.61%, indicating some investor caution. The lack of guidance may have contributed to the stock's decline as investors look for clearer direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.35 | N/A | +14.66% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about future developments. They are focused on their clinical programs and maintaining progress.
Management highlighted ongoing development efforts and the importance of upcoming clinical trials.
They emphasized a commitment to advancing their pipeline despite current challenges.